DeepWork Portfolio Careers

Small molecules T-168 and T-621 for oral administration → T-168 is in clinical phase 2 for neurodegenerative and metabolic diseases → T-168 has been selected for the Neuro-SysMed Parkinson's disease SLEIPNIR trial with funding from Cure Parkinson’s, the Norwegian Parkinson’s Research Fund, the Norwegian Parkinson’s Association and Haukeland University (Norway) → T-621 is in IND enabling studies The dual MOA of PGC-1a and TFEB upregulation is relevant across indications in neuro, metabolic, and other disease areas.